MedTrace Logo

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

NCT00426855 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-04-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the combination of bendamustine and bortezomib in patients with indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia is safe and tolerable.

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

DRUG

Bendamustine

starting with 60 mg/m\^ 2, IV, dose escalation, weekly d1,8,15 q5w

DRUG

Bortezomib

weekly 1.5mg/m\^2, IV, d1,8,15,22 q5w

Sponsors & Collaborators

  • Kantonsspital Aarau

    collaborator OTHER

  • Peter Moosmann

    lead OTHER

Principal Investigators

  • Peter R Moosmann, MD PhD · Cantonal Hospital of Aarau, Switzerland

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-02-28
Completion
2009-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00426855 on ClinicalTrials.gov